MA50144A - Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées - Google Patents

Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées

Info

Publication number
MA50144A
MA50144A MA050144A MA50144A MA50144A MA 50144 A MA50144 A MA 50144A MA 050144 A MA050144 A MA 050144A MA 50144 A MA50144 A MA 50144A MA 50144 A MA50144 A MA 50144A
Authority
MA
Morocco
Prior art keywords
n3pglu
peptid
beta
amyloid antibodies
associated uses
Prior art date
Application number
MA050144A
Other languages
English (en)
Inventor
Ronald Bradley Demattos
Jirong Lu
Ying Tang
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA50144A publication Critical patent/MA50144A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050144A 2017-04-20 2018-04-16 Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées MA50144A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20

Publications (1)

Publication Number Publication Date
MA50144A true MA50144A (fr) 2020-07-29

Family

ID=62111232

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050144A MA50144A (fr) 2017-04-20 2018-04-16 Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées

Country Status (28)

Country Link
US (3) US10647759B2 (fr)
EP (1) EP3612559A1 (fr)
JP (3) JP6900500B2 (fr)
KR (2) KR102567295B1 (fr)
CN (2) CN117024583A (fr)
AR (1) AR111208A1 (fr)
AU (2) AU2018255221B2 (fr)
BR (1) BR112019018810A2 (fr)
CA (1) CA3058482C (fr)
CL (1) CL2019002922A1 (fr)
CO (1) CO2019011349A2 (fr)
CR (1) CR20190445A (fr)
DO (1) DOP2019000241A (fr)
EA (1) EA201992163A1 (fr)
EC (1) ECSP19075146A (fr)
IL (1) IL269003A (fr)
JO (1) JOP20190247A1 (fr)
MA (1) MA50144A (fr)
MX (2) MX2019012445A (fr)
NZ (1) NZ758066A (fr)
PE (1) PE20200011A1 (fr)
PH (1) PH12019502361A1 (fr)
SA (1) SA519410311B1 (fr)
SG (1) SG11201909022PA (fr)
TW (2) TWI705975B (fr)
UA (1) UA126806C2 (fr)
WO (1) WO2018194951A1 (fr)
ZA (1) ZA202007868B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) * 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
PE20212266A1 (es) 2019-03-26 2021-11-30 Janssen Pharmaceutica Nv ANTICUERPOS CONTRA AMILOIDE-ß CON PIROGLUTAMATO Y USOS DE ESTOS
WO2021151011A2 (fr) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Traitement de protéinopathies neurodégénératives à l'aide d'une molécule inhibitrice de l'apoptose fas (faim) ou d'un de ses fragments et/ou mimétiques
EP4222160A1 (fr) 2020-10-02 2023-08-09 Eli Lilly and Company Procédés pour réduire la teneur en protéines de cellules hôtes dans des processus de purification d'anticorps et compositions d'anticorps présentant une teneur réduite en protéines de cellules hôtes
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
WO2022251048A1 (fr) 2021-05-24 2022-12-01 Eli Lilly And Company Anticorps anti-amyloïde bêta et leurs utilisations
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
MX2024004514A (es) * 2021-10-22 2024-05-07 Lilly Co Eli Terapia de combinacion con el inhibidor de o-glcnacasa (oga).
IL312380A (en) * 2021-10-29 2024-06-01 Lilly Co Eli Compounds and methods targeting interleukin-34
MX2024005144A (es) 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a la interleucina-34.
AU2022376931A1 (en) 2021-10-29 2024-05-02 Eli Lilly Company Compounds and methods targeting interleukin-34
WO2023076970A1 (fr) * 2021-10-29 2023-05-04 Eli Lilly And Company Composés et procédés ciblant l'interleukine-34
WO2023150483A1 (fr) 2022-02-03 2023-08-10 Eli Lilly And Company Imagerie de tau régionale pour le diagnostic et le traitement de la maladie d'alzheimer
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
WO2024107683A1 (fr) * 2022-11-17 2024-05-23 Eli Lilly And Company Anticorps bêta-amyloïdes anti-n3pglu, doses et utilisations associées
WO2024133925A1 (fr) 2022-12-22 2024-06-27 Bioarctic Ab Anticorps se liant à abêtape3
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL218883B1 (pl) * 2000-02-24 2015-02-27 Lilly Co Eli Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
JP2006513259A (ja) 2002-07-24 2006-04-20 イノジェネティックス・ナムローゼ・フェンノートシャップ ベータ−アミロイド生成および／または凝集に関連した疾病の防止、処置および診断
EP1666061A1 (fr) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Utilisation d'un anticorps
GEP20115195B (en) 2004-07-30 2011-04-11 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and use thereof
PE20061323A1 (es) * 2005-04-29 2007-02-09 Rinat Neuroscience Corp Anticuerpos dirigidos contra el peptido amiloide beta y metodos que utilizan los mismos
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
KR20110036809A (ko) 2008-06-12 2011-04-11 아피리스 아게 파킨슨병과 관련된 증상을 치료하기 위한 화합물
CA2730073A1 (fr) 2008-07-09 2010-01-14 University Of Zurich Procede d'activation de la neurogenese
EP3047854B1 (fr) 2008-07-21 2018-03-21 Probiodrug AG Dosage d'anticorps de diagnostic
US8795664B2 (en) 2010-06-04 2014-08-05 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Monoclonal antibodies targeting amyloid beta oligomers
MX342782B (es) * 2010-08-12 2016-10-12 Eli Lilly And Company * Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
WO2012021475A2 (fr) * 2010-08-12 2012-02-16 Eli Lilly And Company ANTICORPS CONTRE LE PEPTIDE N3pGLU AMYLOÏDE BÊTA ET LEURS UTILISATIONS
WO2015175769A1 (fr) * 2014-05-15 2015-11-19 Biogen Ma Inc. Procédés de détection d'oligomères bêta-amyloïdes dans des échantillons biologiques
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
TWI703157B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Cd3特異性抗體、治療性雙特異性抗體及其用途
JOP20170004B1 (ar) * 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI735600B (zh) * 2016-07-01 2021-08-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها

Also Published As

Publication number Publication date
AU2018255221A1 (en) 2019-09-19
CA3058482C (fr) 2023-05-09
EA201992163A1 (ru) 2020-03-02
AU2018255221B2 (en) 2021-07-01
JP7227312B2 (ja) 2023-02-21
JP7532571B2 (ja) 2024-08-13
CN110582511A (zh) 2019-12-17
SG11201909022PA (en) 2019-11-28
CL2019002922A1 (es) 2020-03-13
BR112019018810A2 (pt) 2020-05-05
TW202120541A (zh) 2021-06-01
US20180305444A1 (en) 2018-10-25
DOP2019000241A (es) 2019-10-15
JOP20190247A1 (ar) 2019-10-20
US11078261B2 (en) 2021-08-03
AR111208A1 (es) 2019-06-12
UA126806C2 (uk) 2023-02-08
WO2018194951A1 (fr) 2018-10-25
IL269003A (en) 2019-10-31
AU2021203927A1 (en) 2021-07-08
JP2020510081A (ja) 2020-04-02
TW201902924A (zh) 2019-01-16
KR20220011800A (ko) 2022-01-28
US10647759B2 (en) 2020-05-12
KR20190129100A (ko) 2019-11-19
JP2021151253A (ja) 2021-09-30
KR102352670B1 (ko) 2022-01-19
CA3058482A1 (fr) 2018-10-25
TWI789644B (zh) 2023-01-11
SA519410311B1 (ar) 2022-03-20
PH12019502361A1 (en) 2020-07-13
MX2019012445A (es) 2020-01-13
JP6900500B2 (ja) 2021-07-07
PE20200011A1 (es) 2020-01-06
TWI705975B (zh) 2020-10-01
US20200262902A1 (en) 2020-08-20
CN117024583A (zh) 2023-11-10
US20210371509A1 (en) 2021-12-02
KR102567295B1 (ko) 2023-08-16
MX2022011817A (es) 2022-10-10
CO2019011349A2 (es) 2019-10-31
EP3612559A1 (fr) 2020-02-26
ECSP19075146A (es) 2019-10-31
ZA202007868B (en) 2023-06-28
AU2021203927B2 (en) 2024-03-21
JP2023058623A (ja) 2023-04-25
NZ758066A (en) 2022-10-28
CN110582511B (zh) 2023-08-08
CR20190445A (es) 2019-11-06

Similar Documents

Publication Publication Date Title
MA50144A (fr) Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées
FR24C1023I1 (fr) Anticorps thérapeutiques et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
MA49683A (fr) Anticorps anti-cd8 et leurs utilisations
MA46708A (fr) Anticorps anti-pd1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA45235A (fr) Anticorps anti-c5 et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA49687A (fr) Anticorps anti-ctla-4 et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA45690A (fr) Anticorps anti-tgfb, méthodes et utilisations
MA50397A (fr) Anticorps anti-tau et leurs utilisations
MA47694A (fr) Anticorps anti-tigit
MA50618A (fr) Polyrhérapies et leurs utilisations
MA49034A (fr) Anticorps anti-lag3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA52773A (fr) Anticorps anti-cd3 et leurs utilisations
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
MA53184A (fr) Anticorps anti-ox40 et leurs utilisations
MA47268A (fr) Anticorps anti-gpc3
MA45233A (fr) Anticorps anti-gitr et leurs utilisations
MA45543A (fr) Anticorps anti-peptides n3pglu amyloïdes bêta et utilisations associées
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations